Johnson & Johnson: Mood Disorders trials

The registry lists 25 Mood Disorders studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 21Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS PaliperidoneCompletedNCT00892541Phase 1
• A Bioequivalence Study of 15 mg ER OROS PaliperidoneCompletedNCT00892489Phase 1
• A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I DisorderCompletedNCT00892125Phase 1
• A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS PaliperidoneCompletedNCT00838669Phase 1
• A Dose-proportionality Study of Five Tablet Strengths of ER OROS PaliperidoneCompletedNCT00796835Phase 1
• A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release FormulationsCompletedNCT00796640Phase 1
• A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release FormulationsCompletedNCT00796471Phase 1
• A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS PaliperidoneCompletedNCT00796432Phase 1
• A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release PaliperidoneCompletedNCT00796276Phase 1
• As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release FormulationsCompletedNCT00796185Phase 1
• A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform DisorderCompletedNCT00796081Phase 1
• A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral DoseCompletedNCT00796029Phase 1
• A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ERCompletedNCT00791713Phase 1
• A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or QuetiapineCompletedNCT00791622Phase 1
• A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal FunctionCompletedNCT00791401Phase 1
• A Study of QT and QTc Intervals in Patients Administered Immediate Release PaliperidoneCompletedNCT00791349Phase 1
• A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver FunctionCompletedNCT00791284Phase 1
• A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With SchizophreniaCompletedNCT00791232Phase 1
• A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IRCompletedNCT00791193Phase 1
• A Study of the Dose Proportionality of Extended Release PaliperidoneCompletedNCT00791167Phase 1
• A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and VacavilleCompletedNCT00790777Phase 1
• A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I DisorderCompletedNCT00309699Phase 3
• A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I DisorderCompletedNCT00299715Phase 3
• A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar DisorderCompletedNCT00240721Phase 3
• A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I DisorderCompletedNCT00035802Phase 3